Wojciech Legieć

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study

Noopur Raje, Evangelos Terpos, Wolfgang Willenbacher et al. · The Lancet Oncology · 2018 · 441 citations

Medicine, Oncology, Pharmacotherapy +9

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

María‐Victoria Mateos, Hareth Nahi, Wojciech Legieć et al. · The Lancet Haematology · 2020 · 241 citations · Full text

Medicine, Oncology, Pharmacology +14

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial

Saad Z. Usmani, Thierry Façon, Vânia Hungria et al. · Nature Medicine · 2025 · 110 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

Mohamad Mohty, Evangelos Terpos, María‐Victoria Mateos et al. · Clinical Lymphoma Myeloma & Leukemia · 2018 · 89 citations · Full text

Medicine, Hematology, Pharmacoeconomics +14

Thalidomide treatment of resistant or relapsed multiple myeloma patients.

Marek Hus, Anna Dmoszyńska, Maria Soroka‐Wojtaszko et al. · PubMed · 2001 · 85 citations · Full text

Medicine, Hematology, Pharmacotherapy +15